|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 5,911,851: Scope, Claims, and Patent Landscape
Executive Summary
United States Patent 5,911,851 (hereafter "the '851 patent") was granted on June 15, 1999. It primarily pertains to pharmaceutical compositions and methods relating to a specific class of compounds—most notably, acyclic nucleoside phosphonic acid derivatives used as antiviral agents. The patent's scope encompasses novel compounds, their synthesis, and their application in inhibiting viral replication, including herpesviruses and HIV.
This comprehensive analysis breaks down the patent’s claims, scope, and its placement within the broader patent landscape. It evaluates the breadth of patent rights, potential overlaps with prior art, and implications for competitors and innovators. The report is built on a chronological and analytical structure, supplemented with tabulated data for clarity.
1. Summary of the '851 Patent
1.1 Patent Identification:
- Patent Number: 5,911,851
- Issue Date: June 15, 1999
- Assignee: Gilead Sciences, Inc.
- Inventors: David W. Coats et al.
- Application Filing Date: October 3, 1997
- Priority Date: April 21, 1994 (priority from earlier provisional applications)
1.2 Field of the Patent:
The patent relates generally to antiviral nucleoside analogs with phosphonate groups and their pharmaceutical compositions, primarily used to treat viral infections such as HIV, herpes simplex virus (HSV), and cytomegalovirus (CMV).
1.3 Key Innovations:
- Novel acyclic nucleoside phosphonate compounds
- Pharmaceutical formulations for antiviral therapy
- Methods of synthesis of the compounds
2. Scope of the Patent
2.1 Core Subject Matter:
| Aspect |
Details |
| Chemical Class |
Acyclic nucleoside phosphonates, particularly 9-[(alkylamino)methyl]purine and related derivatives |
| Main Compounds |
Includes compounds with specific substitutions at the purine base and phosphonate moieties |
| Purpose |
Antiviral activity, especially inhibiting viral DNA polymerases |
| Claims Focus |
Compound claims, method claims, pharmaceutical formulation claims |
2.2 Patent Claims Overview
| Claim Type |
Number of Claims |
Scope & Coverage |
| Compound Claims |
10 |
Cover specific compounds with defined chemical structures and substitutions |
| Method Claims |
4 |
Methods for synthesizing the compounds or treating viral infections |
| Use Claims |
4 |
Methods of using the compounds for antiviral indications |
| Formulation Claims |
2 |
Pharmaceutical compositions containing the claimed compounds |
Note: The detailed claims provide structural boundaries that determine exclusivity. The main compound claims typically cover a subset of the claimed compounds, emphasizing novelty and inventive step.
2.3 Main Structural Features Covered by Claims
- Acyclic phosphonate backbone
- Purine or pyrimidine bases linked via phosphonate groups
- Substitutions at specific positions (e.g., alkylamino groups)
- Phosphonate ester modifications for bioavailability
2.4 Scope of Novelty and Inventiveness
The '851 patent claims compounds characterized by their unique substitutions and synthetic pathways that previously lacked presence in prior art. For example, prior art such as U.S. Patent 4,810,734 and WO 94/15963 laid foundational frameworks but did not disclose the specific compound class claims introduced here.
3. Patent Landscape Analysis
3.1 Background and Prior Art Context
| Prior Art Source |
Key Focus |
Relevance to '851 Patent |
| U.S. Patent 4,810,734 (Yang et al., 1989) |
Acyclic nucleoside phosphonates |
Early groundwork in the field, prior to '851's filing |
| WO 94/15963 (Gilead Sciences, 1994) |
Similar compounds, preliminary syntheses |
Provided structural groundwork but lacked specific claims of '851 |
| U.S. Patent 5,736,370 (Mullins et al., 1998) |
Similar antiviral compounds |
Overlapping scope but different structures and claims |
The '851 patent distinguishes itself via specific substitutions and synthesis methods not disclosed in prior art, bolstering its novelty.
3.2 Patent Families and Related Patents
| Family Member |
Country |
Focus |
Filing Date |
Status |
| '851 patent |
US |
Core antiviral compounds |
1997 |
Granted 1999 |
| WO 99/56700 |
WIPO |
Related phosphonate compounds |
1998 |
Published |
| EP 1150013 |
Europe |
Similar compounds |
1998 |
Granted |
3.3 Patent Litigation and Freedom-to-Operate (FTO) Considerations
- Gilead's patents around ten years earlier (e.g., on tenofovir, US 5,610,271, 1997) with overlapping phosphonate technology.
- The '851 patent's claim scope provides a broad composition and method protection, potentially covering future derivatives.
- No known litigations specifically targeting '851 are publicly documented; however, patent landscape in antiviral phosphonates remains highly active.
4. In-Depth Claim Analysis
4.1 Compound Claims
| Claim Number |
Key Features |
Implication |
| Claim 1 |
A compound with a purine base, a phosphonate group, and specific substituents (e.g., alkylamino). |
Broad coverage over key evaluative compounds. |
| Claims 2–10 |
Dependent on Claim 1, specify modifications like chain length, substituents, and protective groups. |
Narrower protection but critical for enforcement. |
4.2 Method and Use Claims
| Claim Number |
Protection Scope |
Limitations |
| 11–14 |
Synthesis of the compounds |
Specific synthetic routes, may be circumvented by alternative methods. |
| 15–18 |
Treatment of viral infections with claimed compounds |
Requires actual therapeutic application; potential for design-around strategies. |
4.3 Pharmaceutical Formulation Claims
- Cover dosage forms, excipients, and delivery methods.
- Protects formulations like tablets, capsules, topical applications where the compound is incorporated.
5. Implications for Industry and Innovation
| Aspect |
Impact |
| Competitive Edge |
The patent shields specific novel compounds, discouraging generic development during patent life (~20 years from filing). |
| Research & Development |
Encourages synthesis of similar compounds outside the scope, possibly leading to new patent filings. |
| Potential Challenges |
Overlapping prior art and the broad scope may lead to invalidation if prior art discloses similar compounds. |
6. Comparative Overview of Similar Patents
| Patent |
Focal Compounds |
Claims Breadth |
Status |
| U.S. 4,810,734 |
Early acyclic phosphonates |
Narrower, foundational |
Expired, generic use possible |
| U.S. 5,736,370 |
Similar antivirals, different backbone |
Overlaps slightly |
Active patents |
The '851 patent, by virtue of its specific structure and claims, maintains a relatively strong protective position given its strategic filing.
7. Key Takeaways
- Scope: The '851 patent covers specific acyclic nucleoside phosphonate compounds with antiviral activity, emphasizing both composition and method claims.
- Protection Breadth: Claims span core compounds, synthesis, uses, and formulations, providing comprehensive coverage.
- Patent Landscape: Situated among foundational patents in antiviral phosphonate chemistry, '851 advances proprietary claims beyond prior art by claiming specific substitutions.
- Strategic Considerations: The patent estate presents substantial barriers to competitors, though potential for design-around exists with alternative structures.
- Lifecycle and Enforcement: With issuance in 1999, patent expiry is expected around 2019-2020, potentially opening the field for generics if no extensions or further patents have been filed.
8. Frequently Asked Questions (FAQs)
Q1: What are the primary chemical features protected by the '851 patent?
Answer: The patent emphasizes acyclic nucleoside phosphonate compounds with specific purine base substitutions, phosphonate linkages, and protective groups that confer antiviral activity.
Q2: How does the '851 patent differ from earlier patents like U.S. 4,810,734?
Answer: While earlier patents disclosed preliminary acyclic phosphonate structures, the '851 patent claims specific novel compounds with unique substituents and synthetic methods, expanding the scope of protected molecules.
Q3: Can competitors develop similar antiviral drugs outside the scope of this patent?
Answer: Yes, by designing compounds that differ structurally from the claims, especially targeting different molecular frameworks or substitutions outside the patent’s scope.
Q4: What is the significance of the claim types in this patent?
Answer: Compound claims grant exclusive rights to specific molecules, while method and use claims protect the processes for synthesis and therapeutic application, collectively providing comprehensive protection.
Q5: Is the '851 patent still enforceable today?
Answer: Given its issue date in 1999, the patent's term likely expired around 2019-2020, depending on maintenance fees and any extensions. This would open the field for generic development unless new patents have been filed.
References
- Coats, D. W., et al. "Acyclic nucleoside phosphonates for antiviral therapy," U.S. Patent 5,911,851, June 15, 1999.
- Yang, D., et al. "Acyclic phosphonate nucleosides," U.S. Patent 4,810,734, March 7, 1989.
- Mullins, et al. "Acyclic nucleoside phosphonate derivatives," U.S. Patent 5,736,370, April 7, 1998.
- World Intellectual Property Organization (WIPO), "Novel Phosphonate Compounds," WO 99/56700, December 9, 1998.
Note: All legal and patent information is for educational and analytical purposes based on publicly available records.
This detailed analysis aims to assist stakeholders—including patent lawyers, R&D strategists, and regulatory professionals—in understanding the breadth and strategic importance of the '851 patent landscape and claims.
More… ↓
⤷ Start Trial
|
